

**FORM 6-K**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For the Month of December, 2011

Commission File Number 1-32001

**Lorus Therapeutics Inc.**

---

(Translation of registrant's name into English)

**2 Meridian Road, Toronto, Ontario M9W 4Z7**

---

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):82-\_\_\_\_\_.

---

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Lorus Therapeutics Inc.

Date: December 2, 2011

By: /s/ "Elizabeth Williams"  
Elizabeth Williams  
Director of Finance and Controller

---

**EXHIBIT INDEX**

99.1 REPORT OF VOTING RESULTS


**LORUS THERAPEUTICS INC.  
ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS  
HELD ON NOVEMBER 29, 2011**

**REPORT ON PROXIES**

MOTIONS	NUMBER OF SHARES					PERCENTAGE OF VOTES CAST		
	FOR	AGAINST	WITHHELD	RESTRICTED	NON VOTE	FOR	AGAINST	WITHHELD
Election of Directors	13,322,277	0	23,510		303,914	99.82%	0.00%	0.18%
Appointment of Auditors	13,597,629	0	52,009		66	99.62%	0.00%	0.38%
Approval of Security Based Compensation Plans	13,311,829	33,960	0		303,915	99.75%	0.25%	0.00%
Approval of Amendment to the Terms of Certain Warrants	3,473,752 *	29,685	0	9,842,352	303,915	99.15%	0.85%	0.00%

\* Excluding 9,842,352 shares held by Insiders.

**TOTAL SHAREHOLDERS VOTED BY PROXY:** 73  
**TOTAL SHARES ISSUED & OUTSTANDING:** 21,168,746  
**TOTAL SHARES VOTED:** 13,649,704  
**TOTAL % OF SHARES VOTED:** 64.48%

  
 PAUL ALLEN  
 SCRUTINEER

  
 JAMIE BAJZIK  
 SCRUTINEER